Javascript was detected to be disabled. Javascript is required for some functions on this website.

Health Economics Summer School 2007


Prof. Friedrich Breyer (Konstanz, Germany)
Prof. Friedrich Breyer

Chair of Economic and Social Policy,  University of Konstanz (Germany),  Economics Department.

Member of the executive board and chairman, health economics committee of the association of German-speaking economists (Verein für Socialpolitik); member  of  the  advisory  board of the Federal  Ministry of  Economics and Technology  (Germany);  Research  Professor  at  the  German  Institute of Economic Research in Berlin;  author of a major  health economics textbook.

Prof. Martin J. Buxton (London, England)
Prof. Martin J. Buxton

Professor and Director of the Health Economics Research Group (HERG) at Brunel University, London.

Over 20 years experience in the methods and practice of economic evaluation in health care; previously member of the Appraisal Committee of the National Institute for Clinical Excellence (NICE); member of the Reference Group established by NICE to review the new Single Technology Appraisal (STA) process.

Prof. Sören Holm (Cardiff, Wales)
Prof. Sören Holm

Professorial Fellow in Bioethics at Cardiff Law School, Cardiff University, Wales.

Professor of Medical Ethics at the Universiy of Olso, Norway; editor-in-chief of The Jornal of Medical Ethics; member of the Danish Council of Ethics from 1994 to 1999; currently President-Elect of the European Society for the Philosophy of Medicine and Health Care.

Wolfgang Kaesbach (Essen, Germany)
Wolfgang Kaesbach (Essen, Germany)

Board member of the German Federal Association of Company Sickfunds (Bundesverband der Betriebskrankenkassen, BKK).

Member of the Medicine Evaluation Committee (MEDEV), European Social Health Insurance Forum; head of department of pharmaceutical and medical products at BKK, the lead organization of the German Statutory Health Insurance on pharmaceutical pricing and reimbursement.

Prof. Panos Kanavos (London, England)
Prof. Panos Kanavos

Senior Lecturer in International Health Policy and Merck Fellow in Pharmaceutical Economics at the London School of Economics (LSE) and Professor at the University of Lausanne, Switzerland.

Panos Kanavos has acted as advisor to the World Bank, the World Health Organization, the European Commission, the Organisation for Economic Cooperation and Development (OECD), the American Association for Retired Persons and Ministries of Health as well as other governmental and non-governmental organizations in over 21 transition and developing countries.

Dr. Peter Kolominsky-Rabas (Cologne, Germany)
PD Dr. Peter Kolominsky-Rabas

Head of the Department for Health Economics at the German  Institute  for Quality and Efficiency in Health Care (IQWiG), Cologne (Germany).

Founder and previous Scientific Director of the Interdisciplinary Center for Public Health Studies at the University of Erlangen (Germany); Chairman of the Health Economics and Outcomes Research Committee of the German Stroke Association (DSG); Managing Board Member of the Bavarian Public Health Network.

Prof. Andreas Laupacis (Toronto, Ontario/Canada)
Prof. Andreas Laupacis

Professor,  Department of Health Policy,  Management and Evaluation, at the University of Toronto, and Director, Li Ka Shing Knowledge Institute, Toronto.

Over  20  years  experience in  cost-effectiveness  and quality-of-life  measurement studies; member of Health Canada’s Advisory Board; previously Chief Executive Officer  of the  Institute  for  Clinical  Evaluative  Sciences; formerly  senior  scientist  of  the  Canadian Institutes of  Health Research; first chair of the Canadian Expert Drug Advisory Committee.

Christine Lavery (Amersham, Buckinghamshire/England)
Christine Lavery

Chief Executive, Society for  Mucopolysaccharide and Related Diseases (MPS), Amersham / Buckinghamshire, England (since 1993).

Prior to that, between 1984 and 1993 employed as National Development Officer at Contact a Family, a UK charity;  awarded Member of the British Empire by the Queen in 2002; recipient of A Life Time Award from the International MPS Community for her services to metabolic diseases.

Dr. Ulf Persson (Lund, Sweden)
Dr. Ulf Persson

Research Director at The Swedish Institute for Health Economics (IHE), Lund (Sweden).

Over 20 years research experience in the development and application of economic evaluation methods in health care, with particular regard to the introduction and utilization of medical technologies.

Prof. Jeffrey Richardson (Melbourne, Victoria/Australia)
Prof. Jeffrey Richardson

Professor in the Faculty of Business and Economics at Monash University  ( Melbourne / Clayton, Victoria );
Foundation Director of the Centre for Health Economics (CHE).

President of the Australian Health Economists’ Group from 1984 to 1991; member of the Pharmaceutical Remuneraton Tribunal in Australia; member of the editorial boards of five leading health economic journals.

Prof. Michael Schlander (Wiesbaden, Heidelberg/Mannheim, Ludwigshafen, Germany)*
Prof. Michael Schlander

Founding Chairman of the Institute for Innovation & Valuation in Health Care (InnoValHC); Professor of Health Care Management at the University of Applied Economic Sciences Ludwigshafen (Germany).

Health Economist at the Mannheim Institute of Public Health, Social and Preventive Medicine (University of Heidelberg); over 15 years experience in executive management roles (in clinical research and marketing & as CEO) in the international pharmaceutical industry; author of an in-depth analysis of the NICE multiple technology appraisal process.

Koen Torfs (Neuss, Germany)

Vice President, Health Economics & Public Affairs, Janssen-Cilag GmbH (Neuss, Germany).

Over 20 years experience in the economic evaluation of health care interventions.

Prof. Rosalie Viney (Sydney, New South Wales/Australia)

University of Technology Sydney, Centre for Health Economics Research & Evaluation.

Ph.D. (Economics, Syd), M.Ec. (Tas), B.Ec. (Hons.);  Deputy Director of CHERE, member of the Australian Pharmaceutical Benefits Advisory Committee (PBAC)'s Economics Subcommittee; research focus on the valuation of  health  outcomes  (discrete choice experiments, Quality-Adjusted Life-Years).

*) Scientific Program Director